Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity

作     者：Antonia Stubenvoll Maria Schmidt Johanna Moeller Max Alexander Lingner Chango Carolyn Schultz Olga Antoniadou Henry Loeffler-Wirth Stephan Bernhart Florian Groβe Beatrice Thier Annette Paschen Ulf Anderegg Jan CSimon Mirjana Ziemer Clara TSchoeder Hans Binder Manfred Kunz 

作者机构：Department of DermatologyVenereology and AllergologyUniversity of Leipzig Medical CenterLeipzigGermany Interdisciplinary Center for BioinformaticsUniversity of LeipzigLeipzigGermany Institute for Drug DiscoveryUniversity of Leipzig Medical CenterLeipzigGermany Bioinformatics GroupDepartment of Computer ScienceUniversity of LeipzigLeipzigGermany Department of DiagnosticsFraunhofer Institute of Cell Therapy and Immunology(IZI)LeipzigGermany Center for Scalable Data Analytics and Artificial Intelligence(ScaDS.AI)Dresden/LeipzigLeipzigGermany Department of DermatologyUniversity Hospital EssenUniversity Duisburg-Essen and German Cancer Consortium(DKTK)Partner Site Essen/DüsseldorfEssenGermany 

出 版 物：《Cancer Communications》 (癌症通讯(英文))

年 卷 期：2025年第45卷第4期

页      面：465-470页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Deutsche Forschungsgemeinschaft(DFG)(German Research Foundation,grant numbers:KU 1320/10-1 and HO 6586/1-1,and SFB1430,project 424228829) the Sachsische Aufbaubank(grant number:10071450) 

主　　题：malignant melanoma single cell transcriptomics melanocytic nevus immunity immunotherapy primary melanoma epigenomic analyses epigenomics cd cd interaction 

摘      要：Immunotherapy is currently one of the most promising treatment options for malignant melanoma[1].To uncover new immunological targets for future treatment approaches,single-cell transcriptomic and epigenomic analyses were performed on human primary melanoma(MM)and melanocytic nevus(Nev)samples(Figure 1A).